Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
Caitlin A McIntyreNoah A CohenDebra A GoldmanMithat GonenEran SadotEileen M O'ReillyAnna M VargheseKenneth H YuVinod P BalachandranKevin C SoaresMichael I D'AngelicaJeffrey A DrebinThomas Peter KinghamPeter J AllenAlice C WeiWilliam R JarnaginPublished in: Journal of surgical oncology (2021)
Nearly 20% of patients with locally advanced PDAC responded sufficiently to induction FOLFIRINOX to undergo resection, which was associated with improved OS compared to patients that did not undergo resection. Patients with stable disease who remain unresectable represent a group of patients with locally advanced PDAC who may benefit from optimization of additional nonoperative treatment.